To Investigate the Prevalence of Children Asthma in China

Asthma Clinical Trial

Official title:

To Investigate the Prevalence of Children Asthma in China and Compare With That of the Last 20 Years

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01319292
• Other study ID #: MISP38877
• Status: Completed
• Phase: N/A
• First received: March 17, 2011
• Last updated: August 1, 2014
• Start date: April 2011
• Est. completion date: April 2014

Study information

• Verified date: August 2014
• Source: Capital Institute of Pediatrics, China
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

Asthma is the most common chronic respiratory disease in children and has much effect on their life and study, which leads to huge economic burden and pressure to the whole families. Some children will develop into adult patients so that asthma can be the life-long vigorous trouble. In recent years, the prevalence rate of children asthma is increasingly going up worldwide. The prevalence rate in last 12 months reported in USA, United Kingdom, Australia, New Zealand was between 12% to 30%.

Center for Asthma Prevention and Education of Capital Institute of Pediatrics investigated the national asthma prevalence in 900 thousands children in 27 provinces and cities, which average rate was 0.11% to 2.03% in 1990. In 2000, we investigated it again in 31 provinces(43 cities) and the average national children asthma prevalence rate was 1.97%(0.25% to 4.63%) which was much higher than that in 1990.

Description:

1. Objectives

1. To investigate the national children(0-14 years old)asthma prevalence;

2. To compare the prevalence rate between that in 1990 and 2000;

3. To analyse the asthma manifestations including the ages, seasons, causes, trigger and hereditary factors and their impact on the asthma patients, families and society;

4. To identify the risk factors by questionnaires in case-control research.

2. Study Design / Clinical Plan

1. The screening stage: to distinguish suspected asthma from the children age from 0 to 14 years old.

2. To obtain identified asthma from the suspected asthma.

3. To evaluate the prevalence and severe degree of 0 to 14-year-old children asthma and gain the main risk factors by case-control research.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20000
• Est. completion date: April 2014
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 14 Years

Eligibility

Inclusion Criteria:

• children age from 0 to 14 years

Exclusion Criteria:

Study Design

Observational Model: Ecologic or Community, Time Perspective: Prospective

Related Conditions & MeSH terms

• Asthma

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Capital Institute of Pediatrics, China	Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	prevalence of asthma		Apr 2013	No
Secondary	prevalence of allergic rhinitis		Apr 2013	No